Autorenarchiv: Mighty Medic
2nd Congress of the European Group – International Society for Apheresis (E-ISFA)
12th Lipid Club and Therapeutic Apheresis
May 3-4 2017, Istituto Salesiano Sacro Cuore, Rome Final Program PRESENTATIONS
MightyMedic Workshop on Lipidology and Atherosclerosis – Genoa, Italy – 17 May 2017
LIPIDOLOGY AND ATHEROSCLEROSIS WORKSHOP European Society for Clinical Investigation May 17th, 2017 Preliminary program
HEART UK 31st Annual Medical & Scientific Conference
Cholesterol – A Problem Solved? HEART UK 31st Annual Medical & Scientific Conference Wednesday 5 – Friday 7 July 2017 Warwick Arts Centre, University of Warwick, Coventry CV4 7AL Conference website Register
The Global Gathering For Orphan Drugs
The MIGHTY MEDIC Org FALL SCHOOL of CLINICAL LIPIDOLOGY
The MIGHTY MEDIC Org FALL SCHOOL of CLINICAL LIPIDOLOGY October, 4, 2016
X Congresso Aferesi Terapeutica del Gruppo di Studio della Società Italiana di Nefrologia Napoli, 4 – 5 Novembre 2016 Centro Congressi Via Partenope
X Congresso Aferesi Terapeutica del Gruppo di Studio della Società Italiana di Nefrologia Napoli, 4 – 5 Novembre 2016 Centro Congressi Via Partenope
NOVEMBER 11-12, 2016 VIENNA, AUSTRIA
NOVEMBER 11-12, 2016 VIENNA, AUSTRIA
The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – a post-hoc analysis of a Phase 3, single-arm, open-label trial.
OBJECTIVE: Lomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data …